©The Author(s) 2025.
World J Gastrointest Endosc. Nov 16, 2025; 17(11): 109157
Published online Nov 16, 2025. doi: 10.4253/wjge.v17.i11.109157
Published online Nov 16, 2025. doi: 10.4253/wjge.v17.i11.109157
Table 2 A quick-reference summary of endoscopic bariatric therapies in obese patients
| IGB | ESG | DJBS | TOGA | BTX-A | GES | |
| EWL% | 20%-30% | 50%-60% | 30%-40% | 30%-40% | Uncertain | 25%-35% |
| Reversible | Yes | Partially | Yes | No | Yes | Yes |
| Difficulty1 | 1 | 4 | 2 | 4 | 1 | 2 |
| Metabolic effect | Moderate | Significant | Marked | Good | Limited | Mild |
| Safety | High | Medium-high | Moderate | Moderate | High | Moderate |
- Citation: Zhai YX, Mao T, Li XY, Ren LL, Tian ZB. Advances and future directions in endoscopic bariatric therapies. World J Gastrointest Endosc 2025; 17(11): 109157
- URL: https://www.wjgnet.com/1948-5190/full/v17/i11/109157.htm
- DOI: https://dx.doi.org/10.4253/wjge.v17.i11.109157